Former Chief Operating Officer and President · RECURSION PHARMACEUTICALS, INC. (RXRX)

Tina Marriott

FY2024 is the first fiscal year CompBrief holds for Tina Marriott as a named executive officer of RECURSION PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,893,604

Salary $530,000Stock awards $2,259,736

4th of 6 named executive officers at Recursion Pharmaceuticals by FY2024 total.

6 named officers on file for RECURSION PHARMACEUTICALS, FY2024

Tina Marriott’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • RXRX’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RECURSION PHARMACEUTICALS’s whole pay program stands against its peers

  • RECURSION PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RXRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A).

Free

Get Tina Marriott’s full pay file as a PDF — free

More than this page: up to 10 years of Tina’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Tina Marriott compensation by year

RECURSION PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as RECURSION PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$530,000
Bonus$0
Stock awards$2,259,736
Option awards$2,871,148
Non-equity incentive$213,648
Pension and deferred compensation$0
All other$19,072
Total$5,893,604

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 28, 2025, accession 0001601830-25-000062, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RECURSION PHARMACEUTICALS, INC. filed document, accession 0001601830-25-000062. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU181,967$1,230,097—
RSU122,099$825,389—
RSU24,880$168,189—
Option46,448—$11.40
Option235,154—$8.55
Option354,607—$10.09

Per the Outstanding Equity Awards at Fiscal Year-End table in RECURSION PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments RECURSION PHARMACEUTICALS discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$353,333$0$10,523$575,856
Change in control and involuntary termination$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in RECURSION PHARMACEUTICALS, INC.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

RECURSION PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Najat KhanChief R&D and Chief Commercial Officer$9,194,805
Christopher GibsonChief Executive Officer$8,499,587
Ben TaylorChief Financial Officer$8,171,651
Tina Marriott · this pageFormer Chief Operating Officer and President$5,893,604
Michael SecoraFormer Chief Financial Officer$5,043,506
David MauroChief Medical Officer$1,933,590

The full RECURSION PHARMACEUTICALS compensation record

free company brief

This page is one person within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RECURSION PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RECURSION PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tina Marriott's compensation dossier · One-time report. No refunds.